Vericel Corporation (VCEL) exhibits 74.4% gross margins and 3.4% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 61.4x enterprise multiple and 4.8% implied options volatility.
Sustained 74.4% gross profitability converts into 4.0% operating margin and 3.4% ROIC, outpacing sector cost of capital.
ROIC: 3.4% // GM: 74.4%YoY revenue trajectory of +16.5% paired with 1.13% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +16.5% // FCF YLD: 1.13%Altman Z-Score of 9.94 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 9.94 // F-SCORE: 8/9Trading at 133.0x trailing P/E (111.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 133.0x // EV/EBITDA: 61.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $42.91 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 6.0% net margins.
NET MARGIN: 6.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for VCEL & activate live FRED threshold breach alerts.